Trial Profile
Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Comorbid Anxiety Symptoms.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jan 2012
Price :
$35
*
At a glance
- Drugs Quetiapine (Primary)
- Indications Affective disorders; Anxiety disorders
- Focus Therapeutic Use
- 04 Jan 2012 Actual patient number is 39 according to ClinicalTrials.gov.
- 04 Jan 2012 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 04 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.